In 2019,European Journal of Medicinal Chemistry included an article by Moir, Michael; Lane, Samuel; Lai, Felcia; Connor, Mark; Hibbs, David E.; Kassiou, Michael. Related Products of 128071-75-0. The article was titled 《Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids》. The information in the text is summarized as follows:
Activation of the CB2 receptor is an attractive therapeutic strategy for the treatment of a wide range of inflammatory diseases. However, receptor subtype selectivity is necessary in order to circumvent the psychoactive effects associated with activation of the CB1 receptor. We aimed to use potent, non-selective synthetic cannabinoids designer drugs to develop selective CB2 receptor agonists. Simple structural modifications such as moving the amide substituent of 3-amidoalkylindole synthetic cannabinoids to the 2-position and bioisosteric replacement of the indole core to the 7-azaindole scaffold are shown to be effective and general strategies to impart receptor subtype selectivity. 2-Amidoalkylindole 16 (EC50 CB1 > 10 μM, EC50 CB2 = 189 nM) and 3-amidoalkyl-7-azaindole 21 (EC50 CB1 > 10 μM, EC50 = 49 nM) were found to be potent and selective agonists with favorable physicochem. properties. Docking studies were used to elucidate the mol. basis for the observed receptor subtype selectivity for these compounds The experimental part of the paper was very detailed, including the reaction process of 2-Bromonicotinaldehyde(cas: 128071-75-0Related Products of 128071-75-0)
2-Bromonicotinaldehyde(cas: 128071-75-0) belongs to pyridine. Pyridines are often used as catalysts or reagents; particular notice has been paid recently to how pyridine coordinates to metal centers enabling a wide range of valuable reactions. Related Products of 128071-75-0